Clinical trials
Phase 3 Ovarian Neoplasms trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
64 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 1 |
| 2025 | 4 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Active, not recruiting | 10 |
| Terminated | 9 |
| Unknown status | 8 |
| Recruiting | 6 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Medical Research Council | 7 |
| AstraZeneca | 6 |
| Tesaro, Inc. | 4 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Merck Sharp & Dohme LLC | 3 |
| Pfizer | 3 |
| pharmaand GmbH | 3 |
| AbbVie | 2 |
| Amgen | 2 |
| Novartis Pharmaceuticals | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 64 |
| Fallopian Tube Neoplasms | 23 |
| Carcinoma, Ovarian Epithelial | 22 |
| Peritoneal Neoplasms | 6 |
| Breast Neoplasms | 4 |
| Neoplasms | 4 |
| Endometrial Neoplasms | 3 |
| Testicular Neoplasms | 3 |
| Neoplasm Metastasis | 2 |
| Prostatic Neoplasms | 2 |
Trials
Showing 1 to 25 of 64. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.